Right on Geron

The US Food and Drug Administration's linkurl:decision;http://www.the-scientist.com/blog/display/55353/ to green light a human embryonic stem cell-based therapy for spinal cord injury isn't just good news for the biotech in question, Geron Corp., analysts say -- instead, they argue, the move opens the door to an entire market that has heretofore been stymied. "It's the first clear evidence of the FDA's willingness to permit cells derived from pluripotent stem cells to go into human trials," linkurl:Kenneth Aldrich,;http://people.forbes.com/profile/kenneth-c-aldrich/44832 CEO of Oceanside, Calif.-based linkurl:International Stem Cell Corporation,;http://www.internationalstemcell.com/ told __The Scientist__. "It'll make it easier for us and everyone else, because we now have a roadmap. We know what the FDA wants." "What this essentially says is that the FDA is comfortable with trials involving human embryonic stem cells," said linkurl:Robert Lanza,;http://www.robertlanza.com/ chief scientific officer of Advanced Cell Technology (ACT), a biotech company in Cambridge, Mass. "Now, others moving forward don't have as high a hurdle to jump." "It's an exciting sign that the FDA is satisfied with the initial safety of stem cell therapy," said Stephen Dunn, director of research at Boca Raton, Fla., securities firm linkurl:Dawson James.;http://www.dawsonjames.com/ "At some point the FDA has decided that the benefits outweigh the risks." "The bottom line: Now we're going to get some eff-ing data," said Robin Young, a private analyst who runs the annual Stem Cell summit and was the author of__ linkurl:Stem Cell Analysis and Market Forecasts 2006-2016.;http://www.researchandmarkets.com/reports/480999/stem_cell_analysis_and_market_forecasts_2006.pdf __Nearly all stem cell companies saw their stock prices surge today following Geron's announcement. Investors don't generally differentiate between embryonic and adult stem cells, so "everyone has benefited from this news event," said linkurl:Reni Benjamin,;http://www.rodmanandrenshaw.com/services/research/our_analysts?id=17 managing director and a senior biotechnology analyst at Rodman & Renshaw in New York. "Once one [company] is approved, it paves the road for cellular therapies for other companies to be approved," he added. "This is really a trailblazer." Geron's role in pushing the application forward should not be understated, noted Young. "This was the result of a significant amount of very hard work on the part of Geron. They deserve huge pats on the back for getting this done," he told __The Scientist__. "All eyes are now going to be on the functionality [of the stem cell-derived cells]," said Lanza, who noted that ACT has already consulted with the FDA about using human embryonic stem cell-derived retinal cells to treat blindness, and he expects to file an investigational new drug (IND) application by the summer, "if not before then." Lanza said that the timing of today's decision sends a clear political signal to the industry. "It's not an accident that just a few days after the inauguration of the president this thing moves ahead," he said. "The Republicans always had an antagonistic relationship with the FDA." Most analysts, however, said that the wheels had been turning long before Tuesday's change of leadership. "I don't necessarily believe that there was a political influence," said Benjamin. "This process was started last year when Bush was firmly in office." Karen Riley, an FDA spokesperson, echoed this sentiment. "The timing of the FDA's action was driven by the date the company submitted its application," she told __The Scientist__. "It has absolutely nothing to do with [the inauguration of President Obama]." Benjamin said he was surprised by today's announcement, as most analysts did not expect the FDA's stamp of approval to come this soon. "It's a monumental point in a time," he told __The Scientist__. But the trials will be slow going, he warned. Clinical protocols still need to be approved and staff have to be trained at the seven clinical sites that are participating in the trial, which is expected to enroll around ten patients at a rate of one patient per month. Only one site -- Emory University -- has so far been approved, Benjamin noted, adding that it should take around six months before the trials start, and at least a year before the first data become available. "It's no small feat and a very great achievement, but it's early days and clinical development will still take some time," he said.
**__Related stories:__***linkurl:FDA OKs stem cell trial;http://www.the-scientist.com/blog/display/55353/
[23rd January 2009]*linkurl:Stem cell trial nearly a go?;http://www.the-scientist.com/article/blog/55096/
[17th October 2008]*linkurl:First embryonic stem cell trial stalled;http://www.the-scientist.com/blog/display/54647/
[15th May 2008]

Right on Geron

The Scientist ARCHIVES

Become a Member of

Meet the Author

Elie Dolgin

Related Research Resources

Study Confirms Safety of Genetically Modified T Cells

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

TaqMan Probe & Assays: Unveil What's Possible Together

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Making Real-Time PCR More Straightforward

Products

Product News

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours